Morales Mallory 4

4 · Immuneering Corp · Filed May 23, 2024

Insider Transaction Report

Form 4

Period: 2024-05-21

Immuneering CorpIMRX

Morales Mallory

SVP Finance, CAO

Transactions

Disposition to Issuer
Stock Option
2024-05-21−10,000→ 0 total
Exercise: $6.33Exp: 2032-08-11→ Class A Common Stock (10,000 underlying)
Award
Stock Option
2024-05-21+23,850→ 23,850 total
Exercise: $3.01Exp: 2032-02-10→ Class A Common Stock (23,850 underlying)
Disposition to Issuer
Stock Option
2024-05-21−5,000→ 0 total
Exercise: $5.41Exp: 2032-06-30→ Class A Common Stock (5,000 underlying)
Award
Stock Option
2024-05-21+10,000→ 10,000 total
Exercise: $3.01Exp: 2032-08-11→ Class A Common Stock (10,000 underlying)
Disposition to Issuer
Stock Option
2024-05-21−23,850→ 0 total
Exercise: $9.66Exp: 2032-02-10→ Class A Common Stock (23,850 underlying)
Award
Stock Option
2024-05-21+5,000→ 5,000 total
Exercise: $3.01Exp: 2032-06-30→ Class A Common Stock (5,000 underlying)
Disposition to Issuer
Stock Option
2024-05-21−15,000→ 0 total
Exercise: $9.55Exp: 2033-06-13→ Class A Common Stock (15,000 underlying)
Award
Stock Option
2024-05-21+15,000→ 15,000 total
Exercise: $3.01Exp: 2033-06-13→ Class A Common Stock (15,000 underlying)
Disposition to Issuer
Stock Option
2024-05-21−60,500→ 0 total
Exercise: $6.09Exp: 2034-02-08→ Class A Common Stock (60,500 underlying)
Award
Stock Option
2024-05-21+60,500→ 60,500 total
Exercise: $3.01Exp: 2034-02-08→ Class A Common Stock (60,500 underlying)
Disposition to Issuer
Stock Option
2024-05-21−72,000→ 0 total
Exercise: $4.25Exp: 2033-02-15→ Class A Common Stock (72,000 underlying)
Award
Stock Option
2024-05-21+72,000→ 72,000 total
Exercise: $3.01Exp: 2033-02-15→ Class A Common Stock (72,000 underlying)

Footnotes (7)

[F1]On May 21, 2024, the Issuer's Board of Directors approved an option repricing (the "Repricing") whereby the Reporting Person's options were repriced to an exercise price of $3.01 per share. Under the terms of the Repricing, unless there is a change of control of the Issuer, the exercise price for the repriced options will revert to the original exercise price of the option if, prior to June 30, 2025, the Reporting Person: (i) is terminated by the Issuer for cause or resigns from the Issuer, except by reason of death or disability; or (ii) elects to exercise the repriced options. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
[F2]This option is fully vested.
[F3]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2022, and will be fully vested and exercisable on January 1, 2026.
[F4]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on July 31, 2022, and will be fully vested and exercisable on June 30, 2026.
[F5]The option vests and becomes exercisable (subject to continued service to the Issuer through the applicable vesting date) in forty-eight (48) equal monthly installments following the vesting commencement date of July 1, 2023, and will be fully vested and exercisable on July 1, 2027.
[F6]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.
[F7]The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2023, and will be fully vested and exercisable on January 1, 2027.

Documents

1 file

4
wk-form4_1716495475.xmlPrimary
FORM 4